Medical technology company Enovis Corporation (NYSE:ENOV) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 8.6% year on year to $548.9 million. The company expects the full year’s revenue to be around $2.26 billion, close to analysts’ estimates. Its non-GAAP profit of $0.75 per share was 15.6% above analysts’ consensus estimates. Is now the time to buy ENOV? Find out in our full research report (it’s free for active Edge members). Enovis (ENOV) Q3 CY2025 Highlights: Reven ...